Myomo (MYO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 May, 2026Executive summary
The annual meeting will be held virtually on June 25, 2026, with shareholders voting on key proposals including director elections, executive compensation, auditor ratification, equity plan amendments, and capital structure changes.
Shareholders of record as of April 29, 2026, are eligible to vote, with multiple voting methods available including online, phone, mail, and during the meeting.
The board recommends voting for all management proposals except for the advisory proposal on board declassification, for which it makes no recommendation.
Voting matters and shareholder proposals
Election of two Class III directors (Paul R. Gudonis and Thomas F. Kirk) for terms expiring in 2029.
Advisory (non-binding) vote on executive compensation (say-on-pay).
Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year 2026.
Approval of Amendment No. 3 to the 2018 Stock Option and Incentive Plan, increasing shares available by 1,833,000.
Amendment to the certificate of incorporation to increase authorized common shares to 100,000,000.
Advisory shareholder proposal to declassify the board, moving to annual director elections; board makes no recommendation.
Approval of adjournments if needed to solicit additional proxies.
Board of directors and corporate governance
Board consists of seven members divided into three staggered classes; majority are independent under NYSE American rules.
Board committees include audit, compensation, nominating and corporate governance, and technology, quality and regulatory.
Regular board and committee evaluations are conducted, and a Code of Business Conduct and Ethics is in place.
Shareholders can communicate directly with the board or individual directors.
Latest events from Myomo
- Strong market position, expanding reimbursement, and recurring revenue drive robust growth.MYO
Corporate presentation14 May 2026 - Key votes include director elections, stock plan amendments, and increasing authorized shares.MYO
Proxy filing14 May 2026 - Q1 revenue up 3% to $10.1M, gross margin 68.2%, recurring sources now 49% of revenue.MYO
Q1 202614 May 2026 - Shareholders will vote on key governance, compensation, and capital structure proposals at the annual meeting.MYO
Proxy filing4 May 2026 - Expanding reimbursement and clinical validation drive growth, targeting 158M covered lives by 2026.MYO
Investor presentation7 Apr 2026 - Full-year revenue up 26% to $40.9M, with 2026 guidance at $43–$46M and recurring growth focus.MYO
Q4 20259 Mar 2026 - Aims for $100M revenue by 2028, scaling channels, launching new products, and targeting 70%+ margins.MYO
Investor Day 20253 Feb 2026 - Medicare access and O&P channel expansion fuel record growth and a strong 2025 outlook.MYO
24th Annual Needham Virtual Healthcare Conference3 Feb 2026 - Q2 2024 revenue up 77% to $7.5M, with strong pipeline and breakeven targeted for Q4.MYO
Q2 20242 Feb 2026